SuperSonic Imagine: Solid revenue growth in Q1 2014: +27% to €3.3 million

Regulatory News:

SuperSonic Imagine (Paris:SSI) (Euronext: SSI, FR0010526814, PEA-PME eligible), a company specialized in ultrasound medical imaging, today announces its revenue for the first quarter of 2014.

Unaudited data

SuperSonic Imagine recorded revenue of €3.3m over the 3 months to March 31, 2014, an increase of +27% versus Q1 2013.

Over this first quarter, the Group recorded a 24% increase in the number of Aixplorer^® systems sold as compared to the first quarter of 2013. Given the geographical split and the mix between direct and indirect sales, this represents an increase in sales of +13% to €2.6m, significantly exceeding the growth observed between 2012 and 2013.

The Group regularly books around 40% of its annual sales in the fourth quarter each year. This seasonality effect generally translates into a relatively less significant revenue figure for the first quarter.

Sales of Services totaled €309k over the quarter (+8%), versus €286k a year earlier, and thus continued to account for 11% of total sales.

Other revenue is essentially derived from technology access fees. Although this is a strategic initiative, this revenue is not counted as sales insofar as it is not part of core business and it will not occur regularly.

SuperSonic Imagine is continuing its commercial development across all the geographical regions where Aixplorer^® is being sold. In the first quarter, the EMEA zone represented more than half of the Group’s activity. Asia, which is continuing its growth dynamic initiated in 2012, and the Americas each accounted for almost a quarter of sales.

Gordon Waldron, Executive Vice-President and CFO of SuperSonic Imagine, says: "The revenue recorded over this first quarter, which is traditionally the lowest quarter of the year, was in line with our expectations. This performance and the recent success of our IPO enable us to be confident in our growth prospects over the coming years.”

Jacques Souquet, Founder and CEO of SuperSonic Imagine, concludes: "We are satisfied by the sales generated over the first quarter, which enabled us to exceed the symbolic level of 800 Aixplorer^® systems sold worldwide, notably thanks to the buoyant sales momentum in Asia. This performance confirms the substantial clinical value of our Aixplorer^® ultrasound system and validates the rationale of our development strategy.”

About SuperSonic Imagine

Founded in 2005 and based in Aix-en-Provence (France), SuperSonic Imagine is a company specializing in medical imaging. The company designs, develops and markets a revolutionary ultrasound system, Aixplorer^®, with an UltraFast™ platform that can acquire images 200 times faster than conventional ultrasound systems. Aixplorer^® is the only system that can image two types of waves: ultrasound waves ensure excellent image quality and shear waves, which allow physicians to visualize and analyze the stiffness of tissue in a real-time, reliable, reproducible and non-invasive manner. This innovation, ShearWave™ Elastography, significantly improves the detection and characterization of numerous pathologies in several applications including breast, thyroid, liver and prostate. SuperSonic Imagine has been granted regulatory clearances for the commercialization of Aixplorer^® on the main markets. Over the past years, SuperSonic Imagine enjoyed the backing of several prestigious investors, among which Auriga Partners, Edmond de Rothschild Investment Partners, Bpifrance, Omnes Capital and NBGI.

For more information about SuperSonic Imagine, please go to www.supersonicimagine.com